Impact of high tumor mutational burden in solid tumors and challenges for biomarker application

Volume: 89, Pages: 102084 - 102084
Published: Sep 1, 2020
Abstract
Accurate identification of patients with solid tumors likely to respond to immunotherapy is crucial. Tumor mutational burden (TMB) measures the number of somatic mutations in a tumor and is an emerging prognostic and predictive biomarker for anti-programmed cell death (PD) 1/anti-PD-ligand 1 therapy and other immunotherapeutic agents. Tumor mutational burden is assessed optimally by whole exome sequencing, but next generation sequencing provides...
Paper Details
Title
Impact of high tumor mutational burden in solid tumors and challenges for biomarker application
Published Date
Sep 1, 2020
Volume
89
Pages
102084 - 102084
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.